Chapters

Transcript

Video

What do you recommend regarding the timing for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease? (Korean)


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Seung Tae Kim, MD

Seung Tae Kim, MD

Division of Hematology Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea